TACE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tace, and when can generic versions of Tace launch?
Tace is a drug marketed by Sanofi Aventis Us and is included in three NDAs.
The generic ingredient in TACE is chlorotrianisene. There are four drug master file entries for this compound. Additional details are available on the chlorotrianisene profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TACE?
- What are the global sales for TACE?
- What is Average Wholesale Price for TACE?
Summary for TACE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 1,655 |
| DailyMed Link: | TACE at DailyMed |
US Patents and Regulatory Information for TACE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | TACE | chlorotrianisene | CAPSULE;ORAL | 008102-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sanofi Aventis Us | TACE | chlorotrianisene | CAPSULE;ORAL | 011444-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sanofi Aventis Us | TACE | chlorotrianisene | CAPSULE;ORAL | 016235-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
More… ↓
